Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment.

Liver fibrosis results from an excessive wound healing response in most chronic liver diseases, such as hepatitis C. Despite great advances in antiviral therapy in recent years, progressive liver fibrosis remains a major problem for patients with recurrent hepatitis C after liver transplantation. Liver biopsy remains a central tool in the management of HCV-positive liver transplant recipients, but reliable non-invasive methods for the assessment of liver fibrosis, such as ultrasound elastography, are increasingly being incorporated in the management of post-transplant patients, helping predict prognosis, guide treatment decisions, and stratify patients for emerging antifibrotic therapies. In this manuscript, we will review the natural history as well as tools to monitor fibrosis progression in the HCV-positive liver transplant recipient, the mechanisms underlying rapid fibrosis progression in up to 30% of these patients, the effect of antiviral therapies and highlight promising antifibrotic approaches.

• Publication year

  2013

• Venue

  Journal of Hepatology

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2012.12.014PMID 23262248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin‐28B polymorphism in hepatitis C and liver transplantation

  2013cited by this paper
• IL-17 signaling in inflammatory cells , Kupffer cells and Hepatic Stellate cells exacerbates liver fibrosis

  2013cited by this paper
• Anti-fibrotic therapy: lost in translation?

  2012cited by this paper
• Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy.

  2012cited by this paper
• What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis

  2012cited by this paper
• Understanding the switchbacks: The impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation

  2012cited by this paper
• Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

  2012cited by this paper
• Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

  2012cited by this paper
• Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice.

  2012cited by this paper
• Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

  2012cited by this paper
• A 7‐gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection

  2012cited by this paper
• Ultrasound‐based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: A systematic review and meta‐analysis

  2012cited by this paper
• Noninvasive assessment of liver fibrosis

  2011cited by this paper
• Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.

  2011cited by this paper
• Mechanisms of Lipotoxicity in NAFLD and Clinical Implications

  2011cited by this paper
• Integrating mechanisms of pulmonary fibrosis

  2011cited by this paper
• Interleukin‐28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

  2011cited by this paper
• Targeted therapy of liver fibrosis/cirrhosis and its complications.

  2011cited by this paper
• Metabolic alterations and chronic hepatitis C: treatment strategies

  2011cited by this paper
• What is the long-term outcome of the liver allograft?

  2011cited by this paper
• Liver transplantation and hepatitis C: Will understanding the interleukin‐28B polymorphisms improve outcomes?

  2011cited by this paper
• Hepatitis C Virus Proteins Activate NRF2/ARE Pathway by Distinct ROS-Dependent and Independent Mechanisms in HUH7 Cells

  2011cited by this paper
• Genomic medicine reaches HCV-related liver transplantation: hopes and clinical and public health implications.

  2011cited by this paper
• Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?

  2011cited by this paper
• Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection

  2011cited by this paper
• Protective and pathogenic functions of macrophage subsets

  2011cited by this paper
• Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications

  2011cited by this paper
• Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation

  2011influential reference
• Hepatitis C virus–infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men

  2011influential reference
• Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients.

  2011cited by this paper
• Magnetic Resonance Elastography and Biomarkers to Assess Fibrosis From Recurrent Hepatitis C in Liver Transplant Recipients

  2011cited by this paper
• Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages.

  2011cited by this paper
• Fibrosing Cholestatic Hepatitis in HIV/HCV Co‐Infected Transplant Patients—Usefulness of Early Markers After Liver Transplantation

  2011cited by this paper
• Steatosis and fibrosis progression in patients with recurrent hepatitis C infection: Complex interactions providing diagnostic and therapeutic challenges

  2011cited by this paper
• Donor and Recipient IL28B Polymorphisms in HCV‐Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation

  2011cited by this paper
• A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis

  2011cited by this paper
• Therapeutic targets in liver fibrosis.

  2011cited by this paper
• The International Journal of Biostatistics Non-Markov Multistate Modeling Using Time-Varying Covariates , with Application to Progression of Liver Fibrosis due to Hepatitis C Following Liver Transplant

  2011cited by this paper
• A Systematic Review and Meta-analysis

  2011cited by this paper
• Non‐invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence

  2011cited by this paper
• Assessment of Allograft Fibrosis by Transient Elastography and Noninvasive Biomarker Scoring Systems in Liver Transplant Patients

  2010cited by this paper
• The relationship between liver disease stage and liver fibrosis: a tangled web

  2010cited by this paper
• Portal fibroblasts: Underappreciated mediators of biliary fibrosis

  2010cited by this paper
• Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection.

  2010cited by this paper
• Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

  2010cited by this paper
• Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review

  2010cited by this paper
• Lipid Metabolism and Liver Disease in Hepatitis C Viral Infection

  2010cited by this paper
• Role of Hepatitis C virus core protein in viral‐induced mitochondrial dysfunction

  2010cited by this paper
• Evolving challenges in hepatic fibrosis

  2010cited by this paper
• Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression

  2010cited by this paper
• Amelioration of hepatic fibrosis by NK cell activation

  2010cited by this paper
• Validation of noninvasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantation

  2010cited by this paper
• Chances and limitations of non‐invasive tests in the assessment of liver fibrosis in liver transplant patients

  2010cited by this paper
• Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation

  2010influential reference
• Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation.

  2010influential reference
• HIV and HCV Cooperatively Promote Hepatic Fibrogenesis via Induction of Reactive Oxygen Species and NFκB*

  2010cited by this paper
• Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis

  2009influential reference
• A seven‐gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C

  2009cited by this paper
• Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.

  2009cited by this paper
• gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis

  2009cited by this paper
• Non-invasive biomarkers of liver fibrosis in liver transplant patients with hepatitis C: can we avoid liver biopsies?

  2009cited by this paper
• Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies

  2009cited by this paper
• Antiviral Treatment of Recurrent Hepatitis C After Liver Transplantation: Predictors of Response and Long-Term Outcome

  2009cited by this paper
• Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride

  2009cited by this paper
• Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus–infected liver transplant recipients

  2009cited by this paper
• Liver biopsy

  2009cited by this paper
• Evolution of hepatitis C virus in liver allografts

  2009cited by this paper
• Hepatitis C Virus (HCV) Proteins Induce NADPH Oxidase 4 Expression in a Transforming Growth Factor β-Dependent Manner: a New Contributor to HCV-Induced Oxidative Stress

  2009cited by this paper
• Computer‐assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient

  2009influential reference
• Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course

  2009influential reference
• Assessment of liver stiffness in patients after living donor liver transplantation by transient elastography

  2009cited by this paper
• Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence

  2009cited by this paper
• Recurrent hepatitis C after liver transplantation: On‐treatment prediction of response to peginterferon/ribavirin therapy

  2008cited by this paper
• Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.

  2008cited by this paper
• HIV increases HCV replication in a TGF-beta1-dependent manner.

  2008cited by this paper
• Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation

  2008cited by this paper
• Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation

  2008influential reference
• Cellular and molecular mechanisms of fibrosis

  2008cited by this paper
• Combination of Oxidative Stress and Steatosis Is a Risk Factor for Fibrosis in Alcohol-Drinking Patients With Chronic Hepatitis C

  2008cited by this paper
• Hepatitis C virus infection: Molecular pathways to metabolic syndrome

  2008cited by this paper
• Histologic Abnormalities are Common in Protocol Liver Allograft Biopsies From Patients With Normal Liver Function Tests

  2008cited by this paper
• Hepatitis C virus reinfection in liver transplant patients: Evaluation of liver damage progression with echo‐color doppler

  2008cited by this paper
• The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age

  2008cited by this paper
• The natural history of recurrent hepatitis C and what influences this

  2008cited by this paper
• Protocol Liver Allograft Biopsies

  2008cited by this paper
• Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

  2008cited by this paper
• Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C

  2008influential reference
• Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C

  2008cited by this paper
• Virology and pathogenesis of hepatitis C virus recurrence

  2008cited by this paper
• Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection

  2008cited by this paper
• Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis

  2008cited by this paper
• Pegylated‐interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta‐analysis of prospective controlled studies

  2008cited by this paper
• Assessment of Graft Fibrosis by Transient Elastography in Patients With Recurrent Hepatitis C After Living Donor Liver Transplantation

  2008cited by this paper
• Mechanisms of hepatic fibrogenesis.

  2008cited by this paper
• Liver cirrhosis.

  2008cited by this paper
• Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.

  2007influential reference
• Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

  2007cited by this paper
• Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.

  2007cited by this paper
• Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation

  2007cited by this paper
• Final results of a double‐blind, placebo‐controlled trial of the antifibrotic efficacy of interferon‐γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

  2007cited by this paper

• 만성 C형간염의 최신 치료 업데이트

  2025cites this paper
• The impact of donor liver fibrosis on the outcomes of patients who undergo liver transplant: a cohort study from UNOS database

  2025cites this paper
• The application of B1 inhomogeneity-corrected variable flip angle T1 mapping for assessing liver fibrosis.

  2024cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Development of a Radiomics-Based Model to Predict Graft Fibrosis in Liver Transplant Recipients: A Pilot Study

  2023cites this paper
• Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• A deep learning framework for personalised dynamic diagnosis of graft fibrosis after liver transplantation: a retrospective, single Canadian centre, longitudinal study.

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Quantification of extracellular matrix remodeling for the non-invasive identification of graft fibrosis after liver transplantation

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• Prediction of long‐term morbidity and mortality after liver transplantation using two‐dimensional shear wave elastography compared with liver biopsy

  2022cites this paper
• Effectiveness of Direct-acting Agents After Liver Transplantation and Regression of Biomarkers Post-HCV Treatment: A Real-life Study in Rio de Janeiro.

  2022cites this paper
• Trends and outcomes of liver transplantation among older recipients in the United States

  2022cites this paper
• What Is Hot and New in Basic and Translational Science in Liver Transplantation in 2022? Report of the Basic and Translational Research Committee of the International Liver Transplantation Society.

  2022cites this paper
• Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era.

  2022cites this paper
• Transient elastography correlated to four different histological fibrosis scores in children with liver disease

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Breakthroughs and challenges in the management of pediatric viral hepatitis

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients.

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development.

  2021cites this paper
• Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• HCV and Liver Transplantation

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Evidence-based clinical practice guidelines for Liver Cirrhosis 2020

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Evidence‐based clinical practice guidelines for liver cirrhosis 2020

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Detection of graft fibrosis by vibration-controlled transient elastography in pediatric liver transplant recipients.

  2020cites this paper
• Emerging Management of Hepatitis C in Transplant

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Association of shear-wave elastography with clinical outcomes post-liver transplantation.

  2020cites this paper
• The 13C‐methactin breath test is non‐inferior to liver biopsy in predicting liver‐related death and transplantation: A 7‐year prospective follow‐up study in 132 patients with chronic hepatitis C infection

  2020cites this paper
• Role of Liver Stiffness in the Management of Liver Transplantation: First Experience and Clinical Practice

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update

  2020cites this paper
• Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Role of Innate Immunity in Pediatric Post-transplant Idiopathic Liver Fibrosis

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma

  2020cites this paper
• Performance of B-mode ratio and 2D shear wave elastography for the detection and quantification of hepatic steatosis and fibrosis after liver transplantation

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• Activation of YAP Attenuates Hepatic Damage and Fibrosis in Liver Ischemia-Reperfusion Injury.

  2019cites this paper
• Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients

  2019cites this paper
• Efficacy and safety of an interferon-free regimen for treatment of recurrent hepatitis C virus infection following liver transplant

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper